Trial reportBlood transfusion = Trasfusione del sangue2019
Occult hepatitis B infection among blood donors from Yaoundé, Cameroon.
Trial report in Blood transfusion = Trasfusione del sangue, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prevalence of Hepatitis B Virus Infection in Cameroon: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Seroprevalence of human immunodeficiency virus in African blood donors: a systematic review and meta-analysis.EBioMedicine · 2024Pooled it
- Epidemiology of occult hepatitis B and C in Africa: A systematic review and meta-analysis.Journal of infection and public health · 2022Pooled it
- Hepatitis B immune escape and drug resistance mutations among blood donors in Gabon during the year 2022.Scientific reports · 2026Article
- Unrecognized Transmission Risks of Occult Hepatitis B Virus Infection Among Blood Donors in Central Ethiopia.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Residual transfusion risk of occult hepatitis B transmission associated to genotypes A and E among blood donors in Yaoundé, Cameroon.BMC infectious diseases · 2025Article
- Investigating the prevalence and determinants of HIV, HBV, HCV, andVirusdisease · 2025Article
- The status of occult HBV infection in a high endemic region: risk of community HBV transmission and reactivation.BMC research notes · 2025Article
- Prevalence, Molecular Characterization, and Immune Status Response of Hepatitis B Virus Among Healthcare Workers in Yaoundé General Hospital, Cameroon, During May to June 2024: A Hospital-Based Cross-Sectional Study.Health science reports · 2025Article
- The Issue of Screening for Transfusion-Transmitted Infections in Sub-Saharan Africa Presents Several Challenges: A Review.Advances in hematology · 2025Review
- Observational
- Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review.World journal of hepatology · 2024Article
- Incidence of Occult Hepatitis B Infection (OBI) and hepatitis B genotype characterization among blood donors in Cameroon.PloS one · 2024Article
- HIV-1 residual risk and pre-treatment drug resistance among blood donors: A sentinel surveillance from Gabon.PloS one · 2024Article
- Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China.Human vaccines & immunotherapeutics · 2023Article
- Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients.Frontiers in immunology · 2023Article
- Residual risk of hepatitis B virus transmission through blood donations in Burkina Faso screened with rapid diagnostic tests.Health science reports · 2022Article
- Occult Hepatitis B Virus Infection Among Blood Donors in the Capital City of Addis Ababa, Ethiopia:Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Article
- Prevalence of hepatitis B virus core antibodies among blood donors in Nigeria: Implications for blood safety.African journal of laboratory medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundIn Cameroon, the prevention of hepatitis B virus (HBV) transmission by blood transfusion is still only based on hepatitis B surface antigen (HBsAg) screening. However, occult HBV infection (OBI) characterised by the absence of detectable HBsAg and low level of viral DNA remains a potential threat for blood safety. The prevalence of OBI was investigated in blood donors from Yaoundé to provide evidence-based recommendations to improve HBV blood safety. MATERIAL AND
methodsBlood donations from August 1
resultsOf 1,162 donations analysed, 91 (7.8%) were reactive for HBsAg. All of them were also anti-HBc positive. Among the 1,071 HBsAg negative samples, 522 (48.7%) were reactive for anti-HBc. Six (0.56% of all donations) samples fulfilled the consensus definition of OBI and showed low HBV DNA loads (all <6 IU/mL). Following nested polymerase chain reaction amplifications, HBV DNA sequences were obtained for 4 of these samples (1 nearly whole genome [3123 nt], 2 Pre-S/S regions [1,356 nt], and 1 S region [445 nt]). Phylogenetic analysis identified genotype E in all samples. DISCUSSION: Around 1 in 100 Cameroonian blood donors screened who resulted HBsAg negative and anti-HBc positive carried occult HBV infection. HBsAg alone for screening prospective donors is not sufficient to eliminate the risk of HBV transfusion transmission in Cameroon, and because anti-HBc screening does not seem to be feasible without compromising blood supply, implementation of HBV nucleic acid testing could be considered when possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.